Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | ACP3 | P15309 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MTNR1A | P48039 | 4/20 | 0.42 |
| ▸ | MTNR1B | P49286 | 4/20 | 0.42 |
| ▸ | HTR2C | P28335 | 3/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2126034 | 0.88 | ALDH1A1 (0.54) | CYP1A2CYP2C19ALDH1A1CYP2C9ACP3 | |
| SCHEMBL9352587 | 0.88 | CYP2C19 (0.54) | CYP1A2CYP2C19ALDH1A1CYP2C9ACP3 | |
| SCHEMBL7383920 | 0.86 | CYP2C9 (0.44) | CYP1A2CYP2C19ALDH1A1CYP2C9ACP3 | |
| SCHEMBL7384532 | 0.86 | ALDH1A1 (0.44) | CYP1A2CYP2C19ALDH1A1CYP2C9ACP3 | |
| SCHEMBL7385565 | 0.83 | ALDH1A1 (0.42) | CYP1A2CYP2C19ALDH1A1CYP2C9ACP3 | |
| SCHEMBL7381122 | 0.83 | ALDH1A1 (0.42) | CYP1A2CYP2C19ALDH1A1CYP2C9KMT2A | |
| SCHEMBL28799219 | 0.81 | CYP2C9 (0.47) | CYP1A2CYP2C19ALDH1A1CYP2C9ACP3 | |
| SCHEMBL3443300 | 0.81 | CYP2C9 (0.47) | CYP1A2CYP2C19ALDH1A1CYP2C9ACP3 | |
| SCHEMBL5610042 | 0.81 | ALDH1A1 (0.47) | CYP1A2CYP2C19ALDH1A1CYP2C9ACP3 | |
| SCHEMBL2126036 | 0.81 | ALDH1A1 (0.47) | CYP1A2CYP2C19ALDH1A1CYP2C9KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2014121036-A1 | 5-DEUTERO-2,4-THIAZOLIDINEDIONE AND 5-DEUTERO-2,4-OXAZOLIDINEDIONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | DEUTERX, LLC (US) | 2014-08-07 | — | — | WO | disclosed |
| US-20140221369-A1 | 5-DEUTERO-2,4-THIAZOLIDINEDIONE AND 5-DEUTERO-2,4-OXAZOLIDINEDIONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | DEUTERX, LLC (US) | 2014-08-07 | — | — | US | disclosed |
| US-20130183297-A1 | METHOD OF TREATING CANCERS AND A PHARMACEUTICAL COMPOSITION THAT MAY BE USED IN PRACTICING SAID METHOD | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-07-18 | — | — | US | disclosed |
| US-20120263716-A1 | METHOD OF TREATING CANCERS AND A PHARMACEUTICAL COMPOSITION THAT MAY BE USED IN PRACTICING SAID METHOD | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-10-18 | — | — | US | disclosed |
| US-20120258991-A1 | METHOD OF TREATING A CANCER BY ADMINISTERING A SPECIFIED DRUG | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-10-11 | — | — | US | disclosed |
| US-8263631-B2 | Anti-cancer pharmaceutical compositions and methods for treating patients with cancer | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-09-11 | — | — | US | disclosed |
| US-7811556-B2 | Polymeric modifiers and pharmaceutical compositions | SANKYO COMPANY, LIMITED (JP) | 2010-10-12 | — | — | US | disclosed |
| US-20090028868-A1 | Anti-cancer pharmaceutical compositions and methods for treating patients with cancer | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-01-29 | — | — | US | disclosed |
| EP-1982718-A1 | ANTI-CANCER PHARMACEUTICAL COMPOSITION | Daiichi Sankyo Company, Limited (JP) | 2008-10-22 | — | — | EP | disclosed |
| EP-1611173-B1 | POLYMERIC MODIFIERS AND PHARMACEUTICAL COMPOSITIONS | DAIICHI SANKYO CO LTD (JP) | 2008-03-05 | — | — | EP | disclosed |
| US-6432993-B1 | BENZIMIDAZOLE OR IMIDAZO(4,5-B)PYRIDINE DERIVATES; IMMUNOMODULATORS; ALDOSE REDUCTASE AND LIPOXYGENASE INHIBITORS; DIABETES; PREVENTS LIPID PEROXIDATION; ANTILIPEMIC, HYPOTENSIVE AGENTS | SANKYO COMPANY, LIMITED (JP) | 2002-08-13 | — | — | US | disclosed |
| EP-1167357-A1 | ALPHA-SUBSTITUTED CARBOXYLIC ACID DERIVATIVES | Sankyo Company, Limited (JP) | 2002-01-02 | — | — | EP | disclosed |
| US-6211397-B1 | CHLORINATION OF PHOSPHORANES | BASF AKTIENGESELLSCHAFT (DE) | 2001-04-03 | — | — | US | disclosed |
| CN-1287117-A | Cyclobutene derivatives, preparation method and therapeutic use thereof | SANKYO CO (JP) | 2001-03-14 | — | — | CN | disclosed |
| EP-1070703-A1 | Cyclobutene derivatives | Sankyo Company Limited (JP) | 2001-01-24 | — | — | EP | disclosed |
| EP-1022272-A1 | SUBSTITUTED FUSED HETEROCYCLIC COMPOUNDS | Sankyo Company Limited (JP) | 2000-07-26 | — | — | EP | disclosed |
| EP-0603225-B1 | PROCESS FOR PRODUCING alpha-CHLOR-METHYLEN-TRIORGANYLPHOSPHORANE DERIVATES | BASF AG (DE) | 1997-06-04 | — | — | EP | disclosed |
| EP-0603225-A1 | PROCESS FOR PRODUCING -g(a)-CHLOR-METHYLEN-TRIORGANYLPHOSPHORANE DERIVATES. | BASF AG (DE) | 1994-06-29 | — | — | EP | disclosed |
| WO-1993005053-A1 | PROCESS FOR PRODUCING α-CHLOR-METHYLEN-TRIORGANYLPHOSPHORANE DERIVATES | BASF AKTIENGESELLSCHAFT (DE) | 1993-03-18 | — | — | WO | disclosed |
| EP-0498680-A1 | New beta-amino-alpha-hydroxycarboxylic acids and their use | Sankyo Company Limited (JP) | 1992-08-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140221369-A1 | 5-DEUTERO-2,4-THIAZOLIDINEDIONE AND 5-DEUTERO-2,4-OXAZOLIDINEDIONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | SRD5A2, PPARD, SRD5A1 | CYP1A2 516/4885CYP2C19 300/4885ALDH1A1 963/4885 |
| US-20120258991-A1 | METHOD OF TREATING A CANCER BY ADMINISTERING A SPECIFIED DRUG | RNASE1, MCL1, EWSR1 | CYP1A2 2718/4885CYP2C19 3333/4885ALDH1A1 131/4885 |
| US-20120263716-A1 | METHOD OF TREATING CANCERS AND A PHARMACEUTICAL COMPOSITION THAT MAY BE USED IN PRACTICING SAID METHOD | EGFR, ABL1, ERBB2 | CYP1A2 768/4885CYP2C19 917/4885ALDH1A1 709/4885 |
| US-20090028868-A1 | Anti-cancer pharmaceutical compositions and methods for treating patients with cancer | EGFR, ERBB2, KDR | CYP1A2 3259/4885CYP2C19 1502/4885ALDH1A1 2596/4885 |
| US-20130183297-A1 | METHOD OF TREATING CANCERS AND A PHARMACEUTICAL COMPOSITION THAT MAY BE USED IN PRACTICING SAID METHOD | EGFR, ABL1, ERBB2 | CYP1A2 768/4885CYP2C19 917/4885ALDH1A1 709/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.